Showing 101 - 120 results of 14,881 for search '(( significantly increased decrease ) OR ( significance ((teer decrease) OR (we decrease)) ))*', query time: 0.54s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  7. 107

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  8. 108

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  9. 109
  10. 110

    S8 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  11. 111
  12. 112
  13. 113
  14. 114

    S9 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  15. 115

    S7 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120